Skip to main content

Table 2 Treatment data by group

From: Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study

VariableLevelTNBC (n = 130)MBC (n = 44)Totalp value
Local therapyNone4 (3.1%)1 (2.3%)5 (2.9%)0.8203
Complete mastectomy33 (25.4%)15 (34.1%)48 (27.6%)
Lumpectomy2 (1.5%)1 (2.3%)3 (1.7%)
Radiation therapy2 (1.5%)0 (0.0%)2 (1.1%)
Complete mastectomy + radiation therapy37 (28.5%)13 (29.5%)50 (28.7%)
Lumpectomy + radiation therapy52 (40.0%)14 (31.8%)66 (37.9%)
RadiationYes91 (70.0%)27 (61.4%)118 (67.8%)0.3509
Breast conserving surgeryYes54 (41.5%)15 (34.1%)69 (39.7%)0.4763
Chemotherapy in first year following diagnosisYes119 (91.5%)38 (86.4%)157 (90.2%)0.3782
Anthracycline therapyYes104 (80.0%)34 (77.3%)138 (79.3%)0.6731
Platinum therapyYes17 (13.1%)6 (13.6%)23 (13.2%)1.0000
Taxane therapyYes111 (85.4%)31 (70.5%)142 (81.6%)0.0411
  1. Chemotherapy regimens in which at least 5 patients received were included. p values from a two-sample t test for continuous variables and a Fisher’s exact test for categorical variables. Abbreviations: MBC = metaplastic breast cancer, TNBC = triple-negative breast cancer